FI117758B - Menetelmä heikennettyä varicella zoster -virusta sisältävän rokotteen tuottamiseksi - Google Patents

Menetelmä heikennettyä varicella zoster -virusta sisältävän rokotteen tuottamiseksi Download PDF

Info

Publication number
FI117758B
FI117758B FI945697A FI945697A FI117758B FI 117758 B FI117758 B FI 117758B FI 945697 A FI945697 A FI 945697A FI 945697 A FI945697 A FI 945697A FI 117758 B FI117758 B FI 117758B
Authority
FI
Finland
Prior art keywords
vzv
cells
cell
medium
infected
Prior art date
Application number
FI945697A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI945697A0 (fi
FI945697A (fi
Inventor
Paul A Friedman
Philip J Provost
David L Krah
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/893,295 external-priority patent/US5360736A/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI945697A0 publication Critical patent/FI945697A0/fi
Publication of FI945697A publication Critical patent/FI945697A/fi
Application granted granted Critical
Publication of FI117758B publication Critical patent/FI117758B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI945697A 1992-06-04 1994-12-02 Menetelmä heikennettyä varicella zoster -virusta sisältävän rokotteen tuottamiseksi FI117758B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US89403992A 1992-06-04 1992-06-04
US07/893,295 US5360736A (en) 1992-06-04 1992-06-04 Process for attenuated varicella zoster virus vaccine production
US89329592 1992-06-04
US89403992 1992-06-04
PCT/US1993/004986 WO1993024616A1 (fr) 1992-06-04 1993-05-26 Procede de production d'un vaccin attenue contre l'herpesvirus varicellae
US9304986 1993-05-26

Publications (3)

Publication Number Publication Date
FI945697A0 FI945697A0 (fi) 1994-12-02
FI945697A FI945697A (fi) 1995-01-26
FI117758B true FI117758B (fi) 2007-02-15

Family

ID=27129046

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945697A FI117758B (fi) 1992-06-04 1994-12-02 Menetelmä heikennettyä varicella zoster -virusta sisältävän rokotteen tuottamiseksi

Country Status (28)

Country Link
US (1) US5607852A (fr)
EP (2) EP0573107B1 (fr)
JP (2) JP2599552B2 (fr)
KR (1) KR100350169B1 (fr)
CN (2) CN1069216C (fr)
AT (2) ATE419332T1 (fr)
AU (2) AU4392193A (fr)
BG (1) BG62176B1 (fr)
CA (1) CA2097019C (fr)
CZ (2) CZ289574B6 (fr)
DE (2) DE69334254D1 (fr)
DK (2) DK0573107T3 (fr)
ES (2) ES2317869T3 (fr)
FI (1) FI117758B (fr)
GR (1) GR3036812T3 (fr)
HU (1) HU220080B (fr)
MX (1) MX9303274A (fr)
NO (1) NO314068B1 (fr)
NZ (1) NZ253527A (fr)
PT (2) PT573107E (fr)
RO (1) RO114906B1 (fr)
RS (1) RS50330B (fr)
RU (1) RU2126269C1 (fr)
SK (1) SK279387B6 (fr)
TW (1) TW349868B (fr)
UA (1) UA27137C2 (fr)
WO (1) WO1993024616A1 (fr)
YU (1) YU49210B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2361495A (en) 1994-04-28 1995-11-29 Aviron A novel vzv gene, mutant vzv and immunogenic compositions
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
US20040171152A1 (en) * 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
ATE399855T1 (de) * 1996-10-10 2008-07-15 Invitrogen Corp Tierzellkulturmedium mit pflanzlichen nährstoffen
GB9716611D0 (en) * 1997-08-07 1997-10-08 Cantab Pharmaceuticals Res Ltd Virus preparations and methods
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
GB9804632D0 (en) 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
KR100378909B1 (ko) * 1998-03-18 2003-12-18 주식회사 엘지생명과학 사람세포주를이용한풍진백신의생산수율증대방법
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
WO1999057246A1 (fr) * 1998-05-01 1999-11-11 Life Technologies, Inc. Milieux de culture de cellules animales comprenant des elements nutritifs derives des vegetaux
US20060286668A1 (en) * 1999-04-30 2006-12-21 Invitrogen Corporation Animal-cell culture media comprising non-animal or plant-derived nutrients
US6653069B2 (en) * 2000-01-31 2003-11-25 The Research Foundation For Microbial Diseases Of Osaka University Method for quality control of an attenuated vericella live vaccine
CN1318580C (zh) * 2003-07-10 2007-05-30 北京科兴生物制品有限公司 可满足灭活疫苗生产的sars病毒规模化制备及灭活的方法
US7344839B2 (en) * 2004-12-23 2008-03-18 Aurx, Inc. Virus preparations and methods
EP2069482A4 (fr) * 2006-10-17 2011-08-24 Medimmune Llc Modulation de constituants lipides viraux
US20080294361A1 (en) * 2007-05-24 2008-11-27 Popp Shane M Intelligent execution system for the monitoring and execution of vaccine manufacturing
EP2310495B1 (fr) * 2008-08-11 2017-11-22 Sanofi Pasteur Biologics, LLC Compositions et procédés de production de virus herpès alpha 2
CN101967466A (zh) * 2009-07-28 2011-02-09 新泽西医学院 Orf7缺陷型水痘病毒株、含有该毒株的疫苗及其应用
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
CN101972474B (zh) * 2010-11-11 2012-06-27 长春祈健生物制品有限公司 冻干带状疱疹减毒活疫苗及制备方法
BR112013027247A2 (pt) * 2011-02-24 2017-08-22 Mogam Biotechnology Res Institute Cepas do vírus da varicela-zóster e vacina contra o vírus da catapora e herpes zóster usando as mesmas
WO2014062060A1 (fr) * 2012-10-18 2014-04-24 Erasmus University Medical Center Rotterdam Nouveau procédé de production de vaccin à virus vzv acellulaire à titre élevé
CN103074304B (zh) * 2013-01-28 2016-01-13 江苏健安生物科技有限公司 高水平人二倍体细胞培养水痘-带状疱疹疫苗病毒方法
US10350289B2 (en) 2013-09-05 2019-07-16 Merck Sharp & Dohme Corp. Methods of immunization with varicella zoster virus antigen
CN103740735B (zh) * 2013-12-31 2016-04-06 李越希 化学合成的HSV2病毒gC糖蛋白胞外区基因片段及其表达、应用
WO2016087457A1 (fr) * 2014-12-01 2016-06-09 Transgene Sa Formulations liquides stables de virus de la vaccine
RU2637093C1 (ru) * 2016-12-20 2017-11-29 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Способ получения живой культуральной аттенуированной вакцины для профилактики ветряной оспы
CN107174658B (zh) * 2017-04-29 2020-11-27 安徽智飞龙科马生物制药有限公司 人用水痘病毒灭活疫苗及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660565A (en) * 1968-04-17 1972-05-02 Wistar Inst Rubella vaccine and method
US3555149A (en) * 1968-07-05 1971-01-12 Merck & Co Inc Mumps vaccine and its preparation
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
JPS5341202B2 (fr) * 1974-03-12 1978-11-01
US3961046A (en) * 1974-12-02 1976-06-01 American Cyanamid Company Mumps vaccine and preparation thereof
US4000256A (en) * 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
GB1481650A (en) * 1975-05-06 1977-08-03 Merck & Co Inc Chemical processes and products
JPS5251009A (en) * 1975-10-17 1977-04-23 Morinaga Milk Ind Co Ltd Method of producing drug for treating marrow leukemia
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
JPS5341202A (en) * 1976-09-28 1978-04-14 Fuji Photo Film Co Ltd Novel magnetic recording medium
JPS55147227A (en) * 1979-05-04 1980-11-17 Handai Biseibutsubiyou Kenkyukai Preparrtion of attenuated live mumps vaccine
US4252792A (en) * 1979-09-21 1981-02-24 Douglas Industries, Inc. Injectable rabies vaccine composition and method for preparing same
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS624370A (ja) * 1985-07-01 1987-01-10 Sharp Corp 半導体素子
US5024836A (en) * 1987-05-04 1991-06-18 Merck & Co., Inc. Stable lyophilized live herpes virus vaccine
WO1990003429A1 (fr) * 1988-09-23 1990-04-05 Cetus Corporation Micro-emulsions de lipides pour milieux de culture
US5360736A (en) * 1992-06-04 1994-11-01 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production

Also Published As

Publication number Publication date
RU2126269C1 (ru) 1999-02-20
CZ304594A3 (en) 1995-10-18
BG99227A (bg) 1995-07-28
YU7504A (sh) 2006-08-17
FI945697A0 (fi) 1994-12-02
FI945697A (fi) 1995-01-26
UA27137C2 (uk) 2000-02-28
CN1082923A (zh) 1994-03-02
DK0573107T3 (da) 2001-11-12
EP0573107A2 (fr) 1993-12-08
EP0573107B1 (fr) 2001-10-04
ES2161702T3 (es) 2001-12-16
SK148094A3 (en) 1995-07-11
EP1097988B1 (fr) 2008-12-31
NO944654D0 (no) 1994-12-02
AU673167B2 (en) 1996-10-31
EP0573107A3 (fr) 1995-04-26
RO114906B1 (ro) 1999-08-30
PT573107E (pt) 2002-02-28
SK279387B6 (sk) 1998-10-07
ES2317869T3 (es) 2009-05-01
JPH09107958A (ja) 1997-04-28
US5607852A (en) 1997-03-04
BG62176B1 (bg) 1999-04-30
NO944654L (no) 1995-02-03
KR100350169B1 (ko) 2004-05-20
YU38893A (sh) 1996-02-19
JP3156962B2 (ja) 2001-04-16
JPH06172215A (ja) 1994-06-21
JP2599552B2 (ja) 1997-04-09
HU9403473D0 (en) 1995-02-28
CA2097019C (fr) 2007-07-24
AU4003693A (en) 1993-12-09
DK1097988T3 (da) 2009-05-04
TW349868B (en) 1999-01-11
ATE419332T1 (de) 2009-01-15
EP1097988A1 (fr) 2001-05-09
YU49210B (sh) 2004-09-03
HUT71863A (en) 1996-02-28
CZ289690B6 (cs) 2002-03-13
CN1069216C (zh) 2001-08-08
DE69330850T2 (de) 2002-04-11
ATE206311T1 (de) 2001-10-15
GR3036812T3 (en) 2002-01-31
DE69330850D1 (de) 2001-11-08
CN1307902A (zh) 2001-08-15
PT1097988E (pt) 2009-03-05
AU4392193A (en) 1993-12-30
HU220080B (hu) 2001-10-28
RS50330B (sr) 2009-11-10
CZ289574B6 (cs) 2002-02-13
CA2097019A1 (fr) 1993-12-05
NZ253527A (en) 1996-09-25
NO314068B1 (no) 2003-01-27
WO1993024616A1 (fr) 1993-12-09
DE69334254D1 (de) 2009-02-12
MX9303274A (es) 1994-01-31

Similar Documents

Publication Publication Date Title
FI117758B (fi) Menetelmä heikennettyä varicella zoster -virusta sisältävän rokotteen tuottamiseksi
US5948411A (en) Stabilized live vaccine
US6290967B1 (en) Stabilizers for lyophilized vaccines
US3783098A (en) Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same
JP2005502357A (ja) 細胞培養物中のウイルス増殖
IE51553B1 (en) Herpes simplex type 1 subunit vaccine
US5360736A (en) Process for attenuated varicella zoster virus vaccine production
US4070453A (en) Diploid porcine embryonic cell strains, cultures produced therefrom, and use of said cultures for production of vaccines
US6051238A (en) Stabilizers for lyophilized mumps vaccines
JPH10510708A (ja) 連続継代したアフリカミドリザル腎臓細胞
CA2274755A1 (fr) Stabilisants pour vaccins lyophilises
Geerligs et al. Efficacy and safety of cell associated vaccines against Marek's disease virus grown in a continuous cell line from chickens
US20070111211A1 (en) Integrated viral complexes, methods of production thereof, vaccines containing same and methods of use thereof
US3836626A (en) Canine distemper virus vaccine
RU2819260C2 (ru) Бессывороточная среда для производства птичьей вакцины и ее использование
US3432595A (en) Melanoma cell line of canine origin,its propagation and use,and vaccines derived therefrom
CS252736B1 (cs) Živá atenuovaná vakcína proti parvovírusovej enteritíde noriek a sposob jej přípravy
CS203691B1 (cs) Způsob přípravy suspenze atenuovaného viru

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117758

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: MERCK SHARP & DOHME CORP.

Free format text: MERCK SHARP & DOHME CORP.

PC Transfer of assignment of patent

Owner name: MERCK SHARP & DOHME CORP.

MA Patent expired